|
⚲
|
| Keyboard |
| RA Capital Management LP
✚
|
|
|---|---|
| CRD # | 160174 |
| SEC # | 801-73980 |
| CIK # | 0001346824 |
| AUM | 16.40 B (2026-03-31) |
| Employees | 185 (51% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-778-2500 |
| Address | 200 Berkeley Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Ascendis Pharma A/S | 2.4 | ||
| Vaxcyte Inc | 0.7 | ||
| Rhythm Pharmaceuticals Inc | 0.6 | ||
| TYRA Biosciences Inc | 0.5 | ||
| Sionna Therapeutics Inc | 0.4 | ||
| Edgewise Therapeutics Inc | 0.3 | ||
| Newamsterdam Pharma Co NV | 0.3 | ||
| Nuvalent Inc | 0.3 | ||
| Magenta Therapeutics Inc | 0.2 | ||
| Mineralys Therapeutics Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | RA Capital Nexus Fund IV LP | [2025-08-27] | 195.7 M | |
| Filed 2025-04-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | RA Capital Planetary Health Fund LP | [2023-11-29] | 122.2 M | 118.1 M |
| Filed 2025-07-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Finder's Fee $164,000 · Revenue Decline to Disclose | ||||
| VC | RA Capital Nexus III Fund LP | [2022-02-11] | 881.0 M | 971.9 M |
| Filed 2021-10-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | RA Capital Nexus II Fund LP | [2021-02-26] | 331.9 M | |
| Filed 2020-09-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | RA Capital Nexus Fund LP | [2019-07-12] | 128.9 M | 195.1 M |
| Filed 2019-07-12 (D) · Exemption 506(b), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | RA Capital Healthcare Fund LP | [2012-02-14] | 2,361.1 M | 14.53 B |
| Filed 2025-04-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 16.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 1 | 0.1 |
| (n) Other | 0 | 0.0 |
| Total | 13 | 16.4 |
| By Discretionary | ||
| Discretionary | 13 | 16.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 13 | 16.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.6 | |
| United States Persons | 10.8 | |
| Total | 13 | 16.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Sophia Dilbert | Director | 109 | 44 | |
| James Keyes | Director | 153 | 31 | |
| Sabrina Foster | Director | 43 | 16 | |
| Sherri Fleming | Director | 53 | 12 | |
| Derek Candy | Director | 30 | 8 | |
| Victor Valencia | Director | 14 | 6 | |
| Sinead Wagner | Director | 8 | 3 | |
| Peter Kolchinsky | Director, Executive Officer, Promoter | 42 | 2 | |
| Rajeev Shah | Director, Executive Officer, Promoter | 30 | 2 | |
| Kyle Teamey | Executive Officer | 11 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001346824] | |
| 3 | [0001346824] | |
| 4 | [0001346824] | |
| SC 13D | [0001346824] | |
| SC 13G | [0001346824] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300ZV6X2KFAD7UG21 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-30 | Buy | 971,091 | $6.50 | 6,312,092 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-30 | Buy | 58,300 | $24.16 | 1,408,528 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-27 | Buy | 310,700 | $23.67 | 7,354,269 |
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-27 | Buy | 2,495,623 | $6.43 | 16,046,856 |
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 4,954,558 | $6.06 | 30,024,621 |
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 351,224 | $6.38 | 2,240,809 |
|
Acumen Pharmaceuticals Inc ABOS
Common Stock
|
2026-03-16 | Grant | 6,060,606 | $3.30 | 20,000,000 |
|
Bicara Therapeutics Inc BCAX
Common Stock
|
2026-02-26 | Buy | 300,000 | $16.00 | 4,800,000 |
|
Bicara Therapeutics Inc BCAX
Pre-Funded Warrant (Right to Buy) · derivative
|
2026-02-26 | Buy | 2,200,000 | $16.00 | 35,200,000 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-02-19 | Grant | 6,200 | $0.00 | |
|
Mineralys Therapeutics Inc MLYS
Stock Option (Right to Buy) · derivative
|
2026-02-19 | Grant | 8,300 | $0.00 | |
|
Evommune Inc EVMN
Common Stock
|
2026-02-17 | Grant | 35,868 | $27.88 | 1,000,000 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 767,294 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 3,441,966 | $16.00 | 55,071,456 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 1,150,941 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 248,034 | $16.00 | 3,968,544 |
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 1,806,644 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 222,591 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 272,056 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 2,524,473 | ||
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
RWC Asset Management LLP
✚
|
17.32 B | |
|
Monarch Alternative Capital LP
✚
|
NY | 16.69 B |
|
Compass Rose Asset Management LP
✚
|
NY | 16.50 B |
|
Freestone Grove Partners LP
✚
|
CA | 16.48 B |
|
O'Connor Alternative Investments LLC
✚
|
NY | 16.37 B |
|
Varde Management LP
✚
|
NY | 16.13 B |
|
Whitebox Advisors LLC
✚
|
MN | 15.74 B |
|
Soroban Capital Partners LP
✚
|
NY | 15.67 B |
|
Weiss Asset Management LP
✚
|
MA | 15.56 B |
|
Intech Investment Management LLC
✚
|
FL | 15.47 B |